CytoMed Therapeutics Statistics
Total Valuation
GDTC has a market cap or net worth of $11.66 million. The enterprise value is $10.29 million.
Important Dates
The next estimated earnings date is Friday, April 24, 2026.
| Earnings Date | Apr 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GDTC has 11.54 million shares outstanding. The number of shares has increased by 0.93% in one year.
| Current Share Class | 11.54M |
| Shares Outstanding | 11.54M |
| Shares Change (YoY) | +0.93% |
| Shares Change (QoQ) | -0.00% |
| Owned by Insiders (%) | 17.21% |
| Owned by Institutions (%) | 0.50% |
| Float | 3.68M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 12.97 |
| Forward PS | 43.51 |
| PB Ratio | 2.30 |
| P/TBV Ratio | 2.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 11.56 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.17, with a Debt / Equity ratio of 0.07.
| Current Ratio | 5.17 |
| Quick Ratio | 5.17 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -189.85 |
Financial Efficiency
Return on equity (ROE) is -50.28% and return on invested capital (ROIC) is -29.46%.
| Return on Equity (ROE) | -50.28% |
| Return on Assets (ROA) | -27.48% |
| Return on Invested Capital (ROIC) | -29.46% |
| Return on Capital Employed (ROCE) | -54.55% |
| Weighted Average Cost of Capital (WACC) | 3.10% |
| Revenue Per Employee | $20,692 |
| Profits Per Employee | -$71,969 |
| Employee Count | 43 |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.56% in the last 52 weeks. The beta is -0.21, so GDTC's price volatility has been lower than the market average.
| Beta (5Y) | -0.21 |
| 52-Week Price Change | -57.56% |
| 50-Day Moving Average | 1.02 |
| 200-Day Moving Average | 1.68 |
| Relative Strength Index (RSI) | 45.11 |
| Average Volume (20 Days) | 7,887 |
Short Selling Information
The latest short interest is 117,191, so 1.02% of the outstanding shares have been sold short.
| Short Interest | 117,191 |
| Short Previous Month | 137,172 |
| Short % of Shares Out | 1.02% |
| Short % of Float | 3.19% |
| Short Ratio (days to cover) | 4.62 |
Income Statement
In the last 12 months, GDTC had revenue of $889,748 and -$3.09 million in losses. Loss per share was -$0.27.
| Revenue | 889,748 |
| Gross Profit | 836,887 |
| Operating Income | -3.09M |
| Pretax Income | -3.11M |
| Net Income | -3.09M |
| EBITDA | -2.77M |
| EBIT | -3.09M |
| Loss Per Share | -$0.27 |
Full Income StatementBalance Sheet
The company has $1.63 million in cash and $375,176 in debt, with a net cash position of $1.25 million or $0.11 per share.
| Cash & Cash Equivalents | 1.63M |
| Total Debt | 375,176 |
| Net Cash | 1.25M |
| Net Cash Per Share | $0.11 |
| Equity (Book Value) | 5.33M |
| Book Value Per Share | 0.43 |
| Working Capital | 2.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$2.87 million and capital expenditures -$495,907, giving a free cash flow of -$3.38 million.
| Operating Cash Flow | -2.87M |
| Capital Expenditures | -495,907 |
| Depreciation & Amortization | 312,675 |
| Net Borrowing | -41,686 |
| Free Cash Flow | -3.38M |
| FCF Per Share | -$0.29 |
Full Cash Flow StatementMargins
| Gross Margin | 94.06% |
| Operating Margin | -346.82% |
| Pretax Margin | -349.20% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
